SS
CTKB icon

SBI Securities’s Cytek Biosciences CTKB Stock Holding History

SBI Securities’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Sell
3,010
-2,000
-40% -$8.54K ﹤0.01% 1703
2026
Q1 		$21.9K Hold
5,010
– – ﹤0.01% 1419
2025
Q4 		$25.3K Buy
5,010
+2,500
+100% +$11.6K ﹤0.01% 1348
2025
Q3 		$8.71K Sell
2,510
-10
-0.4% -$38 ﹤0.01% 1828
2025
Q2 		$8.57K Buy
2,520
+2,500
+12,500% +$8.33K ﹤0.01% 1769
2025
Q1 		$80 Buy
20
+10
+100% +$52 ﹤0.01% 3517
2024
Q4 		$65 Buy
+10
New +$60 ﹤0.01% 3574

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SBI Securities's CTKB Position: Q2 2026 in Review

SBI Securities reduced its Cytek Biosciences (CTKB) stake by 40% in Q2 2026, selling an estimated $8.54K and leaving 3,010 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

SBI Securities first reported a position in CTKB in Q4 2024 and has held it in 7 quarters since. The position peaked at $25.3K in Q4 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • SBI Securities held 3,010 shares of Cytek Biosciences worth $13.3K as of Q2 2026.
  • SBI Securities sold 2,000 Cytek Biosciences shares in Q2 2026, an estimated $8.54K.
  • Cytek Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1703 holding.
  • SBI Securities first reported a position in Cytek Biosciences in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Cytek Biosciences position peaked at $25.3K in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.